# CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

> **NCT06927648** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 130 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06927648
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2029-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927648, "CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06927648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*